Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
This is a randomised trial with experimental and active comparator arms. Participants in Experimental Arm 1 will receive 0.006mg/kg bempegaldesleukin (NKTR-214), administered intravenously in combination with 360mg nivolumab, every 3 weeks. Participants in the Active Comparator arm will receive 480mg nivolumab alone, administered intravenously every 4 weeks.